CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
February 2014—Chembio Diagnostics has entered a follow-on, milestone-based development agreement with a private contracting organization acting on behalf of the Centers for Disease Control and Prevention for a multiplex POC influenza immunity test using Chembio’s patented Dual Path Platform technology.
The project contemplates a timeline of three months to optimize the multiplex assay to determine a person’s influenza immunity status in the field or in an outpatient setting, while incorporating certain additional subunits of influenza virus proteins.
Chembio Diagnostics, 631-924-1135